{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:49Z","timestamp":1785265129098,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.7759\/cureus.113526","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:01Z","timestamp":1785262501000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Biliary Cholangitis in the Middle East: A Review of Current Challenges and Treatment Approaches"],"prefix":"10.7759","author":[{"given":"Faisal M","family":"Sanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah  S","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Khathlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Alqutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Al Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Y","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H","family":"Mawardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira Y","family":"Al-Tarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"AlNahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella J","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023, 7:e0179. 10.1097\/HC9.0000000000000179","journal-title":"Hepatol Commun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis","volume":"113","author":"Sarcognato S","year":"2021","unstructured":"Sarcognato S, Sacchi D, Grillo F, et al.. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021, 113:170-84. 10.32074\/1591-951X-245","journal-title":"Pathologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: a comprehensive review","volume":"40","author":"Lleo A","year":"2020","unstructured":"Lleo A, Leung PS, Hirschfield GM, Gershwin EM. The pathogenesis of primary biliary cholangitis: a comprehensive review. Semin Liver Dis. 2020, 40:34-48. 10.1055\/s-0039-1697617","journal-title":"Semin Liver Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield GM","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, et al.. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression","volume":"29","author":"Degott C","year":"1999","unstructured":"Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology. 1999, 29:1007-12. 10.1002\/hep.510290444","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Cortez-Pinto H","year":"2021","unstructured":"Cortez-Pinto H, Liberal R, Lopes S, et al.. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J. 2021, 9:699-706. 10.1002\/ueg2.12095","journal-title":"United European Gastroenterol J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.01.030","article-title":"Treatment in primary biliary cholangitis: beyond ursodeoxycholic acid","volume":"124","author":"van Hooff MC","year":"2024","unstructured":"van Hooff MC, Werner E, van der Meer AJ. Treatment in primary biliary cholangitis: beyond ursodeoxycholic acid. Eur J Intern Med. 2024, 124:14-21. 10.1016\/j.ejim.2024.01.030","journal-title":"Eur J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2018.09.001","article-title":"PBC-transplantation and disease recurrence","volume":"34-35","author":"Nevens F","year":"2018","unstructured":"Nevens F. PBC-transplantation and disease recurrence. Best Pract Res Clin Gastroenterol. 2018, 34-35:107-11. 10.1016\/j.bpg.2018.09.001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002070","article-title":"Application of the latest advances in evidence-based medicine in primary biliary cholangitis","volume":"118","author":"Kowdley KV","year":"2023","unstructured":"Kowdley KV, Bowlus CL, Levy C, Mayo MJ, Pratt DS, Vuppalanchi R, Younossi ZM. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am J Gastroenterol. 2023, 118:232-42. 10.14309\/ajg.0000000000002070","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv T","year":"2021","unstructured":"Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021, 36:1423-34. 10.1111\/jgh.15329","journal-title":"J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.sjg_112_21","article-title":"Cholestatic liver disease: practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation","volume":"27","author":"Mawardi M","year":"2021","unstructured":"Mawardi M, Alalwan A, Fallatah H, et al.. Cholestatic liver disease: practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation. Saudi J Gastroenterol. 2021, 27:S1-26. 10.4103\/sjg.sjg_112_21","journal-title":"Saudi J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9151525","article-title":"The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta\u2010analysis","volume":"2021","author":"Gazda J","year":"2021","unstructured":"Gazda J, Drazilova S, Janicko M, Jarcuska P. The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta\u2010analysis. Can J Gastroenterol Hepatol. 2021, 2021:9151525. 10.1155\/2021\/9151525","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002464","article-title":"Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe","volume":"35","author":"Murillo Perez CF","year":"2023","unstructured":"Murillo Perez CF, Gerussi A, Trivedi PJ, et al.. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe. Eur J Gastroenterol Hepatol. 2023, 35:112-9. 10.1097\/MEG.0000000000002464","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms MH","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al.. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019, 71:357-65. 10.1016\/j.jhep.2019.04.001","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2019.00049","article-title":"Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches","volume":"8","author":"Galoosian A","year":"2020","unstructured":"Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 2020, 8:49-60. 10.14218\/JCTH.2019.00049","journal-title":"J Clin Transl Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, et al.. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018, 16:1342-50.e1. 10.1016\/j.cgh.2017.12.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Li J, Haller IV, et al.. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol. 2018, 16:1333-41.e6. 10.1016\/j.cgh.2017.10.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro F","year":"2022","unstructured":"Colapietro F, Bertazzoni A, Lleo A. Contemporary epidemiology of primary biliary cholangitis. Clin Liver Dis. 2022, 26:555-70. 10.1016\/j.cld.2022.06.001","journal-title":"Clin Liver Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis","volume":"13","author":"Zeng N","year":"2019","unstructured":"Zeng N, Duan W, Chen S, et al.. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int. 2019, 13:788-99. 10.1007\/s12072-019-09984-x","journal-title":"Hepatol Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.sjg_445_21","article-title":"Efficacy of ursodeoxycholic acid for primary biliary cholangitis: experience from a tertiary care centre in Saudi Arabia","volume":"29","author":"AlWabel AH","year":"2023","unstructured":"AlWabel AH, Peedikayil M, AlNasser S, et al.. Efficacy of ursodeoxycholic acid for primary biliary cholangitis: experience from a tertiary care centre in Saudi Arabia. Saudi J Gastroenterol. 2023, 29:135-40. 10.4103\/sjg.sjg_445_21","journal-title":"Saudi J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-03105-7","article-title":"Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center","volume":"24","author":"Nejad SE","year":"2024","unstructured":"Nejad SE, Heiat M, Javanbakht M, Alavian SM, Haris MA. Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center. BMC Gastroenterol. 2024, 24:17. 10.1186\/s12876-023-03105-7","journal-title":"BMC Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00347","article-title":"Guidelines on the diagnosis and management of primary biliary cholangitis (2021)","volume":"11","author":"You H","year":"2023","unstructured":"You H, Duan W, Li S, et al.. Guidelines on the diagnosis and management of primary biliary cholangitis (2021). J Clin Transl Hepatol. 2023, 11:736-46. 10.14218\/JCTH.2022.00347","journal-title":"J Clin Transl Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.041","article-title":"The diagnosis of primary biliary cirrhosis","volume":"13","author":"Bowlus CL","year":"2014","unstructured":"Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev. 2014, 13:441-4. 10.1016\/j.autrev.2014.01.041","journal-title":"Autoimmun Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019, 114:48-63. 10.1038\/s41395-018-0390-3","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2018.03.008","article-title":"Liver biopsy in primary biliary cholangitis: indications and interpretation","volume":"22","author":"Tan D","year":"2018","unstructured":"Tan D, Goodman ZD. Liver biopsy in primary biliary cholangitis: indications and interpretation. Clin Liver Dis. 2018, 22:579-88. 10.1016\/j.cld.2018.03.008","journal-title":"Clin Liver Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot C","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al.. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008, 48:871-7. 10.1002\/hep.22428","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08742-w","article-title":"Review of current and upcoming second-line treatments for primary biliary cholangitis","volume":"70","author":"Cumpian NA","year":"2025","unstructured":"Cumpian NA, Choi G, Saab S. Review of current and upcoming second-line treatments for primary biliary cholangitis. Dig Dis Sci. 2025, 70:100-10. 10.1007\/s10620-024-08742-w","journal-title":"Dig Dis Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019, 69:394-419. 10.1002\/hep.30145","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac101","article-title":"IgG and IgM immunohistochemistry in primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) liver explants","volume":"158","author":"Hsu M","year":"2022","unstructured":"Hsu M, Ju JY, Pearson MM, Yu L, Swanson PE, Yeh MM. IgG and IgM immunohistochemistry in primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) liver explants. Am J Clin Pathol. 2022, 158:770-3. 10.1093\/ajcp\/aqac101","journal-title":"Am J Clin Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84828-0_194","article-title":"Primary biliary cirrhosis, overview","author":"Poupon R","year":"2014","unstructured":"Poupon R. Primary biliary cirrhosis, overview. Encyclopedia of Medical Immunology. Mackay IR, Rose NR, Diamond B, Davidson A (ed): Springer , New York; 2014. 884-9. 10.1007\/978-0-387-84828-0_194"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14929","article-title":"Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis","volume":"35","author":"Joshita S","year":"2020","unstructured":"Joshita S, Yamashita Y, Sugiura A, et al.. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. J Gastroenterol Hepatol. 2020, 35:1208-14. 10.1111\/jgh.14929","journal-title":"J Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot C","year":"2022","unstructured":"Corpechot C, Carrat F, Gaouar F, et al.. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022, 77:1545-53. 10.1016\/j.jhep.2022.06.017","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101107","article-title":"Systematic review and meta-analysis: transient elastography compared to liver biopsy for staging of liver fibrosis in primary biliary cholangitis","volume":"28","author":"Manzo-Francisco LA","year":"2023","unstructured":"Manzo-Francisco LA, Aquino-Matus J, Vida\u00f1a-P\u00e9rez D, Uribe M, Chavez-Tapia N. Systematic review and meta-analysis: transient elastography compared to liver biopsy for staging of liver fibrosis in primary biliary cholangitis. Ann Hepatol. 2023, 28:101107. 10.1016\/j.aohep.2023.101107","journal-title":"Ann Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo MJ","year":"2022","unstructured":"Mayo MJ. Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?. Hepatology. 2022, 76:518-31. 10.1002\/hep.32405","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2010.07.018","article-title":"The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis","volume":"35","author":"Kuiper EM","year":"2011","unstructured":"Kuiper EM, Hansen BE, Lesterhuis W, et al.. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2011, 35:29-33. 10.1016\/j.gcb.2010.07.018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts SB","year":"2020","unstructured":"Roberts SB, Ismail M, Kanagalingam G, et al.. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun. 2020, 4:1332-45. 10.1002\/hep4.1518","journal-title":"Hepatol Commun"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari R","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, et al.. 6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002, 45:3569-72. 10.1021\/jm025529g","journal-title":"J Med Chem"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016, 375:631-43. 10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"ref39","article-title":"Obeticholic acid","author":"Krupa KN","year":"2026","unstructured":"Krupa KN, Nguyen H, Parmar M. Obeticholic acid. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref40","unstructured":"European Medicines Agency (EMA). EMA recommends revoking conditional marketing authorisation for Ocaliva. (2025). Accessed: June 9, 2025: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-revoking-conditional-marketing-authorisation-ocaliva.."},{"key":"ref41","unstructured":"Intercept voluntarily withdraws obeticholic acid (Ocaliva) for PBC from US market. (2024). Accessed. July 10, 2026: https:\/\/www.hcplive.com\/view\/intercept-voluntarily-withdrawals-obeticholic-acid-ocaliva-for-pbc-from-us-market."},{"key":"ref42","unstructured":"Intercept Pharmaceuticals. Intercept announces voluntary withdrawal of OCALIVA\u00ae for primary biliary cholangitis (PBC) from the US market; US clinical trials involving obeticholic acid placed on clinical hold. (2025). Accessed: July 10, 2026: https:\/\/www.globenewswire.com\/news-release\/2025\/09\/11\/3148535\/23024\/en\/Intercept-Announces-Voluntary-Withdrawal-of-OC...."},{"key":"ref43","unstructured":"Gilead Sciences. Gilead\u2019s Livdelzi\u00ae (seladelpar) granted accelerated approval for primary biliary cholangitis by U.S. FDA. (2024). Accessed: July 10, 2026: https:\/\/www.gilead.com\/news\/news-details\/2024\/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-bi...."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield GM","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al.. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024, 390:783-94. 10.1056\/NEJMoa2312100","journal-title":"N Engl J Med"},{"key":"ref45","unstructured":"Ipsen. Ipsen's Iqirvo\u00ae (elafibranor) receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis. (2024). Accessed: July 10, 2026: https:\/\/www.ipsen.com\/press-release\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-trea...."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03798-x","article-title":"Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis","volume":"20","author":"Gelhorn H","year":"2025","unstructured":"Gelhorn H, Currie BM, Bushnell DM, et al.. Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis. Orphanet J Rare Dis. 2025, 20:459. 10.1186\/s13023-025-03798-x","journal-title":"Orphanet J Rare Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby A","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OFW, Jones DEJ. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005, 54:1622-9. 10.1136\/gut.2005.065862","journal-title":"Gut"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman S","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010, 162:587-93. 10.1111\/j.1365-2133.2009.09586.x","journal-title":"Br J Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley KV","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al.. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024, 390:795-805. 10.1056\/NEJMoa2306185","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00904-2","article-title":"Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis","volume":"23","author":"Zhang H","year":"2023","unstructured":"Zhang H, Li S, Feng Y, Zhang Q, Xie B. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Clin Exp Med. 2023, 23:1741-9. 10.1007\/s10238-022-00904-2","journal-title":"Clin Exp Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot C","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al.. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018, 378:2171-81. 10.1056\/NEJMoa1714519","journal-title":"N Engl J Med"},{"key":"ref52","unstructured":"GSK. Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC). (2026). Accessed: July 10, 2026: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/lynavoy-linerixibat-approved-by-the-us-fda\/."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000857","article-title":"Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis","volume":"9","author":"Gungabissoon U","year":"2022","unstructured":"Gungabissoon U, Gibbons DC, Requena G, Ribeiro de Souza A, Smith H. Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterol. 2022, 9:e000857. 10.1136\/bmjgast-2021-000857","journal-title":"BMJ Open Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08050-9","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo MJ","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, et al.. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023, 68:4064-5. 10.1007\/s10620-023-08050-9","journal-title":"Dig Dis Sci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000216","article-title":"Understanding fatigue and pruritus in primary biliary cholangitis","volume":"23","author":"Faisal A","year":"2024","unstructured":"Faisal A. Understanding fatigue and pruritus in primary biliary cholangitis. Clin Liver Dis (Hoboken). 2024, 23:e0216. 10.1097\/CLD.0000000000000216","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and management of pruritus in primary biliary cholangitis","volume":"26","author":"D\u00fcll MM","year":"2022","unstructured":"D\u00fcll MM, Kremer AE. Evaluation and management of pruritus in primary biliary cholangitis. Clin Liver Dis. 2022, 26:727-45. 10.1016\/j.cld.2022.06.009","journal-title":"Clin Liver Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer AE","year":"2024","unstructured":"Kremer AE, Mayo MJ, Hirschfield GM, et al.. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2024, 80:27-37. 10.1097\/HEP.0000000000000728","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch","volume":"100","author":"Cevikbas F","year":"2020","unstructured":"Cevikbas F, Lerner EA. Physiology and pathophysiology of itch. Physiol Rev. 2020, 100:945-82. 10.1152\/physrev.00017.2019","journal-title":"Physiol Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.15-4-351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade VS","year":"2015","unstructured":"Hegade VS, Kendrick SF, Jones DE. Drug treatment of pruritus in liver diseases. Clin Med (Lond). 2015, 15:351-7. 10.7861\/clinmedicine.15-4-351","journal-title":"Clin Med (Lond)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review","volume":"68","author":"Smith HT","year":"2023","unstructured":"Smith HT, de Souza AR, Thompson AH, McLaughlin MM, Dever JJ, Myers JA, Chen JV. Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review. Dig Dis Sci. 2023, 68:2710-30. 10.1007\/s10620-023-07862-z","journal-title":"Dig Dis Sci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2015-100618","article-title":"A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis","volume":"7","author":"Hegade VS","year":"2016","unstructured":"Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol. 2016, 7:158-66. 10.1136\/flgastro-2015-100618","journal-title":"Frontline Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro F","year":"2023","unstructured":"Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun. 2023, 6:100188. 10.1016\/j.jtauto.2023.100188","journal-title":"J Transl Autoimmun"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg KM","year":"2011","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011, 54:374-85. 10.1016\/j.jhep.2010.09.002","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/496254-primary-biliary-cholangitis-in-the-middle-east-a-review-of-current-challenges-and-treatment-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:03Z","timestamp":1785262503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/496254-primary-biliary-cholangitis-in-the-middle-east-a-review-of-current-challenges-and-treatment-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.113526","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}